glp-1r agonist 1

GLP-1R agonist 1, a thickened imidazole derivative, is a potent agonist of GLP-1R with potential applications in diabetes research.

GLP-1R agonist 10 is a GLP-1 agonist (EC50: 0.051 nM).

GLP-1R agonist 12 (Compound 123) is utilized in diabetes mellitus research as a glucagon-like peptide-1 receptor (GLP-1R) agonist.

GLP-1R agonist 17 is a potent GLP-1 receptor agonist with excellent efficacy in activating the GLP-1 receptor, primarily used in cardiovascular metabolic disease research.

GLP-1R agonist 14, also known as Compound 14, is a potent agonist of the GLP-1 receptor, demonstrating an EC50 range of 0-20 nM against human GLP-1 [1].

GLP-1R agonist 15 (Compound 101) is a GLP-1 receptor agonist [1].

Compound 115a, a GLP-1R agonist, effectively activates the GLP-1 receptor with an EC50 of 0.15 nM [1].

GLP-1R agonist 18 (example 117) acts as an agonist at GLP-1R, exhibiting an EC50 of 0.044 nM [1].

GLP-1R agonist 19 (M3190) is a potent, selective GLP-1 receptor agonist that demonstrates excellent plasma and liver microsomal stability, along with low hERG toxicity [1].

GLP-1R/GIPR agonist-1 is a dual receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). It mimics the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while suppressing glucagon release, thus lowering blood sugar. This compound is used in research related to metabolic disorders such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH).

GLP-1R/GIPR agonist-1 sodium is the sodium salt form of GLP-1R/GIPR agonist-1. It acts as a dual agonist for the glucagon-like peptide-1 receptor (GLP-1R, EC50 = 0.57 nM) and the glucose-dependent insulinotropic polypeptide receptor (GIPR, EC50 = 0.75 nM). GLP-1R/GIPR agonist-1 sodium lowers blood glucose by mimicking the effects of endogenous hormones GLP-1 and GIP, enhancing insulin secretion, and inhibiting glucagon secretion. This compound is applicable in research on metabolic disorders such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH).

Semaglutide is a glucagon-like peptide 1 receptor (GLP-1R) agonist(EC50 of 6.2 pM in a reporter assay using BHK cells expressing the human receptor).

Semaglutide Acetate is a GLP-1R agonist (EC50=6.2 pM) with long-acting, selective, competitive, and oral efficacy. Semaglutide acetate can be used in the study of type 2 diabetes.

GLP-1R Agonist DMB is an agonist of glucagon-like peptide 1 receptor (GLP-1R; KB = 26.3 nM for the recombinant human receptor).

Retatrutide (LY3437943) is a triple agonist of the glucagon receptor, glucose-dependent insulinotropic polypeptide receptor, and glucagon-like peptide-1 receptor (GLP-1R), and inhibits GCGR, GIPR, and GLP-1R.Retatrutide can be used to study obesity.

GLP-1 receptor agonist 4 is a glucagon-like peptide-1 receptor (GLP-1R) agonist with an EC50 of 64.5 nM, and is utilized in diabetes treatment research.

GLP-1 receptor agonist 2 is a glucagon-like peptide-1 receptor (GLP-1R) agonist.

PF-06882961 is an orally bioavailable glucagon-like peptide-1 receptor (GLP-1R) agonist.

Compound 1, also known as GLP-1R agonist 26, is an agonist of the glucagon-like peptide-1 receptor (GLP-1R) with an EC50 of <10 nM.

GLP-1 receptor agonist 17-d3 (Compound 701) is the deuterated form of GLP-1R agonist 17, which acts as a GLP-1 receptor agonist and is applicable in cardiovascular and metabolic disease research.

ZP3022 is a dual agonist targeting the glucagon-like peptide 1 receptor (GLP-1R) and cholecystokinin 2 (CCK2) receptor. It selectively enhances cAMP accumulation or ERK phosphorylation in HEK293 cells with GLP-1R or CCK2 receptor expression, compared to ERK phosphorylation in cells with the CCK1 receptor (EC50s: 0.02, 10.3, and >1,000 nM for human receptors, respectively). At 40 nM, ZP3022 promotes proliferation of rat neonatal β-cells in vitro. It also boosts glucose-induced insulin secretion (GSIS) in rat pancreatic islets at 10 and 100 nM concentrations and decreases body weight in rats at 40 nmol/kg doses twice daily. Administered at 100 nmol/kg daily, ZP3022 enhances β-cell and total pancreatic mass and improves glucose tolerance in db/db mice, while reducing food intake but not body weight in these mice.

GLP-1R agonist 21 (Compound I-134) is an agonist of the glucagon-like peptide-1 receptor (GLP-1 receptor) with an EC50 of 0.0104 nM.

GLP-1R agonist 22 (Compound I-135) functions as an agonist for the glucagon-like peptide-1 receptor (GLP-1 receptor), with an EC50 of 0.0165 nM.

GLP-1R agonist 20 (Compound I-132) is an agonist of the glucagon-like peptide-1 receptor (GLP-1 receptor), with an EC50 value of 0.0162 nM.